United Therapeutics (UTHR) is a publicly traded Healthcare sector company. As of October 8, 2026, UTHR trades at $532.90 with a market cap of $23.38B and a P/E ratio of 18.24. UTHR moved -2.30% today. Year to date, UTHR is +7.26%; over the trailing twelve months it is +18.68%. Its 52-week range spans $266.98 to $609.35. Analyst consensus is buy with an average price target of $638.75. Rallies surfaces UTHR's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
United Therapeutics CEO Martine Rothblatt disposes of USD 4.88 million in common shares: United Therapeutics Chairperson and CEO Martine A. Rothblatt exercised options for 9,500 shares at USD 117.76 on Oct. 7, 2026. A family trust sold 9,500 shares that day at weighted-average prices ranging from USD 542.7339 to USD 556.4848, ending with 324,443 shares.
| Metric | Value |
|---|---|
| Price | $532.90 |
| Market Cap | $23.38B |
| P/E Ratio | 18.24 |
| EPS | $30.23 |
| Dividend Yield | 0.00% |
| 52-Week High | $609.35 |
| 52-Week Low | $266.98 |
| Volume | 722.52K |
| Avg Volume | 0 |
| Revenue (TTM) | $3.15B |
| Net Income | $1.31B |
| Gross Margin | 86.14% |
12 analysts cover UTHR: 0 strong buy, 9 buy, 2 hold, 1 sell, 0 strong sell. Consensus rating is buy. Average price target: $638.75.